Tetraphase Pharmaceuticals to Present Data at IDWeek 2017
September 25 2017 - 9:05AM
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage
biopharmaceutical company developing novel antibiotics to treat
life-threatening multidrug-resistant (MDR) infections, today
announced upcoming data presentations at Infectious Disease Week
(IDWeek) 2017, taking place October 4-8 in San Diego, CA. In total,
five presentations will be given including pharmacokinetic data
from clinical studies supporting eravacycline’s potential use in
patients with renal or hepatic impairment as well as from the
company’s ongoing oral eravacycline development program.
Details for the data presentations at IDWeek 2017 are as
follows:
Eravacycline Data Presentations:Poster
#1829: Pharmacokinetics (PK) of Eravacycline in Subjects
with Renal or Hepatic Impairment Compared to Healthy
SubjectsDate and time: Saturday, October 7, 12:30
– 2:00 p.m. PTSession info: 231 - Clinical Study
with New Antibiotics and Antifungals, Poster Hall CD
Poster #1832: Impact of Meal Timing on
Eravacycline Exposure During the Oral Portion of an IV to Oral
Transition Dosing RegimenDate and time: Saturday,
October 7, 12:30 – 2:00 p.m. PTSession info: 231 -
Clinical Study with New Antibiotics and Antifungals, Poster Hall
CD
Poster #1209: In Vitro Activity of Eravacycline
and Comparator Antimicrobials Against 143 Strains of Bacteroides
Species.Date and time: Friday, October 6, 12:30 –
2:00 p.m. PTSession info: 147 - Expanded Spectrum
– New Antimicrobial Susceptibility Testing, Poster Hall CD
Presentation #866: EravacyclineDate and
time: Thursday, October 5, 3:21 p.m.
PTSpeaker: Patrick Horn, MD, Ph.D.Session
info: Symposium 088: New Antibiotics: What’s in the
Pipeline?, Room 20ABCDFollow-up Q&A Session, Friday, October 6,
7:00 – 8:15 a.m. PT; Meet-the-Professor Session 107 – Pipeline 2.0,
Room 06DE
Surveillance Data Presentation:Poster
#396: Trends in Resistant Enterobacteriaceae (ENT),
Acinetobacter baumannii (ACB) and Extended Spectrum Beta-Lactamase
(ESBL) Organisms in Hospitalized Patients in the US:
2011-2016Date and time: Thursday, October 5, 12:30
– 2:00 p.m. PTSession info: 052 - HAI:
MDRO-GNR/Emerging Resistant Bacterial Pathogens, Poster Hall CD
Additional Activities:
- Tetraphase will be hosting an Exhibit Booth (#527) at IDWeek
2017 from 10:00 – 2:00 p.m. PT, Thursday, October 5 through
Saturday, October 7.
- Tetraphase has provided an independent educational grant in
support of a Continuing Medical Education Lunch Symposium entitled
“Evaluating Emerging Options for Complicated and Multi-Drug
Resistant Infections: Case-Based Considerations.” It will take
place on Wednesday, October 4, 11:00 am – 1:00 pm PT at the
Marriott Marquis San Diego Marina, Ballroom F and G.
IDWeek is the combined annual meeting of the Infectious Diseases
Society of America (IDSA), the Society for Healthcare Epidemiology
of America (SHEA), the HIV Medicine Association (HIVMA), and the
Pediatric Infectious Diseases Society (PIDS). Full abstracts can be
found on the ID Week website at http://www.idweek.org/
About Tetraphase Pharmaceuticals,
Inc.Tetraphase is a clinical-stage biopharmaceutical
company using its proprietary chemistry technology to create novel
antibiotics for serious and life-threatening bacterial infections,
including those caused by many of the multidrug-resistant (MDR)
bacteria highlighted as urgent public health threats by the CDC.
Tetraphase has created more than 3,000 novel tetracycline analogs
using its proprietary technology platform. Tetraphase's pipeline
includes three antibiotic clinical candidates: eravacycline, which
is in a phase 3 clinical program, and TP-271 and TP-6076, which are
in phase 1 clinical trials. Please visit www.tphase.com for more
company information.
Investor Contacts:Tetraphase
PharmaceuticalsTeri Dahlman617-600-7040tdahlman@tphase.com
Argot PartnersMaeve
Conneighton206-899-4940maeve@argotpartners.com
Media Contact:Sam Brown Inc.Mike
Beyer312-961-2502Mikebeyer@sambrown.com
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Apr 2023 to Apr 2024